News - Oncology, Pfizer

Filter

Current filters:

OncologyPfizer

Popular Filters

1 to 25 of 85 results

Pfizer to acquire generics firm InnoPharma for up to $360 million

Pfizer to acquire generics firm InnoPharma for up to $360 million

17-07-2014

Having failed (so far) in its mega billion dollar ($116 billion) attempt to buy Anglo-Swedish drug major…

GenericsInnoPharmaMergers & AcquisitionsOncologyOphthalmicsPfizer

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Pfizer inks multi-million $ cancer immunology deal with Cellectis

Pfizer inks multi-million $ cancer immunology deal with Cellectis

18-06-2014

France-based genome engineering specialist Cellectis saw its shares rocket nearly 50% to 9.26 euros,…

CellectisLicensingMergers & AcquisitionsOncologyPfizerPharmaceutical

Pfizer to submit NDA for breast cancer drug palbociclib later this year

18-05-2014

US pharma giant Pfizer says that it will submit a New Drug Application with the US Food and Drug Administration…

OncologypalbociclibPfizerPharmaceuticalRegulationUSA

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

AstraZeneca says Pfizer offer “very significantly” undervalues the firm

28-04-2014

Confirming a takeover approach from the US drugs giant, Anglo-Swedish pharma major AstraZeneca issued…

AstraZenecaMergers & AcquisitionsOncologyPfizerPharmaceutical

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

Pfizer palbociclib trial disappoints, despite meeting primary endpoint

08-04-2014

At the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, US pharma giant…

AmgenOncologypalbociclibPfizerPharmaceuticalResearch

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

25-03-2014

US pharma behemoth Pfizer says that PROFILE 1014, a Phase III study of anaplastic lymphoma kinase (ALK)…

OncologyPfizerPharmaceuticalResearchXalkori

Strong mid-stage trial results for Pfizer’s palbociclib in advanced breast cancer

Strong mid-stage trial results for Pfizer’s palbociclib in advanced breast cancer

03-02-2014

Positive results from a randomized Phase II trial [PALOMA-1] of US pharma giant Pfizer’s palbociclib…

OncologypalbociclibPfizerPharmaceuticalResearch

Pfizer’s dacomitinib fails in two late-stage NSCLC studies

Pfizer’s dacomitinib fails in two late-stage NSCLC studies

28-01-2014

US pharma giant Pfizer has released disappointing top-line results from two randomized Phase III studies…

dacomitinibOncologyPfizerPharmaceuticalResearch

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Puma Biotech rockets on positive results with neratinib in I-SPY 2 TRIAL

06-12-2013

USA-based development-stage firm Puma Biotechnology saw its shares leap 42% to nearly $66 in morning…

BiotechnologyneratinibOncologyPfizerPuma BiotechResearch

Negative NICE appraisal of Pfizer’s Bosulif for CML

Negative NICE appraisal of Pfizer’s Bosulif for CML

27-11-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRare diseasesRegulation

Pfizer and GSK link up to trial combo melanoma therapy

Pfizer and GSK link up to trial combo melanoma therapy

22-11-2013

Two of the world’s pharma giants, USA-based Pfizer and the UK’s GlaxoSmithKline have joined forces…

GlaxoSmithKlineMekinistOncologypalbociclibPfizerPharmaceuticalResearchtrametinib

Pfizer’s Xalkori gains regular FDA approval for NSCLC

Pfizer’s Xalkori gains regular FDA approval for NSCLC

22-11-2013

The US Food and Drug Administration yesterday (November 21) granted pharma behemoth Pfizer’s Xalkori…

North AmericaOncologyPfizerPharmaceuticalRegulationXalkori

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

Gliknik enters licensing agreement with Pfizer

30-09-2013

Gliknik has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, which is…

BiotechnologyGliknikImmunologicalsLicensingNorth AmericaOncologyPfizer

Oxford BioMedica earns Pfizer milestone

28-08-2013

UK, gene-based biopharma company Oxford BioMedica (LSE: OXB) says it has received a $1 million milestone…

BiotechnologyFinancialOncologyOxford BioMedicaPF-06263507PfizerResearch

Onyx Pharma accepts increased bid from Amgen

27-08-2013

Amgen (Nasdaq: AMGN), the world largest independent biotech group, said on Sunday (August 25) that the…

AmgenBayerBiotechnologyKyprolisMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizer

NICE says Xalkori is not cost effective in ALK-positive NSCLC

20-08-2013

US pharma behemoth Pfizer (NYSE: PFE) has today (August 16) expressed concern and disappointment that…

EuropeOncologyPfizerPharmaceuticalPricingRegulationXalkori

1 to 25 of 85 results

Back to top